We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+11.77%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.63B
AUM Growth
-$1.1B
Cap. Flow
-$741M
Cap. Flow %
-20.41%
Top 10 Hldgs %
50.26%
Holding
130
New
22
Increased
12
Reduced
43
Closed
31

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$43.3M
2
PODD icon
Insulet
PODD
+$22.7M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$21.9M
4
SEPN
Septerna Inc
SEPN
+$17.7M
5
PEN icon
Penumbra
PEN
+$16.7M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$88.3M
2
BHVN icon
Biohaven
BHVN
+$74.2M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$50.4M
4
APGE
Apogee Therapeutics
APGE
+$49.4M
5
APLT
Applied Therapeutics
APLT
+$44.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JANX icon
26
Janux Therapeutics
JANX
$1.01B
$43.8M 1.21%
+817,895
New +$43.3M
ARGX icon
27
argenx
ARGX
$61.3B
$41.5M 1.14%
67,471
-51,368
-43% -$30.1M
VKTX icon
28
Viking Therapeutics
VKTX
$3.49B
$40.1M 1.1%
995,894
-704,093
-41% -$40.1M
PRAX icon
29
CALL
Praxis Precision Medicines
PRAX
$8.74B
$38.5M 1.06%
+500,000
New +$36.2M
AKRO
30
DELISTED
Akero Therapeutics
AKRO
$33M 0.91%
1,185,592
-529,214
-31% -$16M
ISRG icon
31
Intuitive Surgical
ISRG
$133B
$32.9M 0.91%
63,119
+5,000
+9% +$2.6M
ACRV icon
32
Acrivon Therapeutics
ACRV
$78.4M
$32.3M 0.89%
5,360,858
– –
ZYME icon
33
Zymeworks
ZYME
$1.86B
$31.2M 0.86%
2,130,020
-50,000
-2% -$699K
CELC icon
34
Celcuity
CELC
$4.05B
$30.9M 0.85%
2,362,279
– –
VRDN icon
35
Viridian Therapeutics
VRDN
$2.47B
$28.5M 0.79%
1,486,508
-1,326,157
-47% -$28.8M
SLDB icon
36
Solid Biosciences
SLDB
$897M
$27.6M 0.76%
6,906,646
– –
AMLX icon
37
Amylyx Pharmaceuticals
AMLX
$3.69B
$25.6M 0.71%
6,774,348
+4,648,699
+219% +$21.9M
PRCT icon
38
Procept Biorobotics
PRCT
$1.11B
$23.4M 0.65%
290,659
-25,000
-8% -$2.14M
NAUT icon
39
Nautilus Biotechnolgy
NAUT
$113M
$21.2M 0.58%
12,594,211
– –
CTNM
40
Contineum Therapeutics
CTNM
$520M
$21.1M 0.58%
1,441,249
-75,419
-5% -$1.19M
NTRA icon
41
Natera
NTRA
$50.6B
$19.8M 0.55%
125,000
-95,000
-43% -$13.8M
IKT icon
42
Inhibikase Therapeutics
IKT
$322M
$19.3M 0.53%
+5,925,000
New +$14.8M
OBIO icon
43
Orchestra BioMed
OBIO
$363M
$18.4M 0.51%
4,592,556
– –
PEN icon
44
Penumbra
PEN
$12.5B
$17.4M 0.48%
+73,338
New +$16.7M
SEPN
45
Septerna Inc
SEPN
$1.81B
$17.2M 0.47%
+750,000
New +$17.7M
ORKA
46
Oruka Therapeutics
ORKA
$6.1B
$16.4M 0.45%
845,567
-389,620
-32% -$9.5M
INBX icon
47
Inhibrx
INBX
$1.55B
$16.4M 0.45%
1,064,026
– –
ADMA icon
48
ADMA Biologics
ADMA
$1.93B
$15.3M 0.42%
890,280
-169,920
-16% -$3.2M
DRUG
49
Bright Minds Biosciences
DRUG
$591M
$14.5M 0.4%
+403,649
New +$14.2M
ARVN icon
50
Arvinas
ARVN
$540M
$14.2M 0.39%
740,749
-287,000
-28% -$6.97M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Perceptive Advisors held 130 positions worth $3.63B, down 23% from $4.73B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $741M in Q4 2024, closing 31 positions and reducing 43 holdings. Its most notable exit was Biohaven, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Janux Therapeutics worth $43.8M.

  • Perceptive Advisors's largest Q4 2024 buy was Janux Therapeutics: 817,895 shares worth $43.8M.
  • Perceptive Advisors added most to Insulet in Q4 2024, an estimated $22.7M increase.
  • Perceptive Advisors's biggest Q4 2024 reduction was Soleno Therapeutics, cutting an estimated $88.3M.
  • Perceptive Advisors fully exited Biohaven in Q4 2024, selling an estimated $74.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.63B portfolio in Q4 2024.
  • Perceptive Advisors opened 22 new positions and closed 31 in Q4 2024.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $3.63B.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.